Adalimumab improves treatment satisfaction with medication (TS-M) in patients with moderate to severe hidradenitis suppurativa (HS) in a 12-week randomized controlled trial (PIONEER II) - 09/05/15
Gregor B. E. Jemec, MD, Roskilde Hospital, University of Copenhagen, Roskilde, Denmark; Murali Sundaram, MBA, PhD, AbbVie, North Chicago, IL, United States; Brett Pinsky, PhD, AbbVie, North Chicago, IL, United States; Lei Shu, PhD, AbbVie, North Chicago, IL, United States; Martin Okun, MD, PhD, AbbVie, North Chicago, IL, United States; Yanjun Bao, PhD, AbbVie, North Chicago, IL, United States
Le texte complet de cet article est disponible en PDF. Funding statement: Design, study conduct, and financial support for the study were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the abstract. All authors contributed to the development of the publication and maintained control over the final content. |
Vol 72 - N° 5S1
P. AB39 - mai 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?